Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
Orpha Labs AG is working with investigators to switch patients from a compassionate use study initiated last year to this Phase III study.
Feb 23, 2022, 08:00 ET
First Patient to Receive ORL-101 in Israel This Week
Feb 08, 2021, 02:00 ET